SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has named veteran medtech finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. The appointment comes as the company accelerates its global expansion and pursues U.S. Food and Drug Administration clearance for its SSi Mantra surgical robotic system.
Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised over $100 million during her career. She previously served as CFO at Vicarious Surgical, another robotic surgical technology developer, where she led financial and operational initiatives to reduce cash burn and strengthen the balance sheet. Her expertise is expected to be pivotal as SS Innovations navigates the capital-intensive process of regulatory approval and commercialization.
The company is actively preparing for U.S. FDA review of the SSi Mantra system (https://nnw.fm/yY4UM), a key milestone that could open the world’s largest healthcare market for its robotic surgery platform. While awaiting U.S. clearance, SS Innovations has been expanding internationally, recently graduating the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program. The program welcomed 33 healthcare professionals from seven countries, underscoring the company’s emphasis on surgeon education alongside technology deployment.
This dual focus on regulatory advancement and global training highlights SS Innovations’ strategy to build a comprehensive ecosystem for robotic surgery adoption. The appointment of a CFO with deep capital markets experience suggests the company may be positioning itself for further fundraising or strategic partnerships to support its growth ambitions.
For investors, the timing of Romanos’s appointment signals SS Innovations’ commitment to financial discipline and transparency as it prepares for potential FDA approval. The company’s recent training program demonstrates tangible progress in building a global user base, which could accelerate adoption once regulatory hurdles are cleared. However, the company faces risks common to medtech startups, including clinical trial outcomes, regulatory timelines, and competition from established players like Intuitive Surgical.
SS Innovations has not provided a specific timeline for FDA submission or approval. The company’s forward-looking statements, as noted in its filings, are subject to risks and uncertainties that could cause actual results to differ materially from expectations. More information is available in the company’s newsroom at https://ibn.fm/SSII.
The broader implications of this appointment and the company’s expansion efforts are significant for the surgical robotics industry. As robotic surgery becomes more accessible globally, SS Innovations’ focus on training and cost-effective technology could democratize advanced surgical care, particularly in underserved regions. Romano’s financial expertise will be crucial in navigating the challenges ahead, ensuring the company can sustain its momentum while managing the complexities of global regulatory and market entry.
